Daiichi Sankyo Submits WelChol sNDA For Diabetes Indication
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo is seeking an expanded indication for its LDL-cholesterol lowering agent WelChol (colesevelam HCI) to improve glycemic control in patients with type 2 diabetes. If approved, the drug would be the first LDL lowering medication also indicated for improving glycemic control.
You may also be interested in...
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required.)